Lessons Learned from a Military–Biotechnology Partnership to Develop a Broad-Spectrum Small-Molecule Inhibitor for Snakebite Envenoming

Snakebite envenoming causes an estimated 138,000 deaths annually worldwide, with approximately 75% of fatalities occurring prior to arrival at definitive medical care. Even in regions where antivenom is available in hospitals, the absence of treatment options before a victim can reach definitive care results in delays of many hours before therapy is initiated. Manufacturing complexity, region-specific products, and the risk of anaphylaxis further limit the availability and use of antivenom in many regions. Reducing the persistently high mortality of snakebite envenoming requires both novel scientific approaches and partnerships that extend beyond traditional disciplinary and funding silos. This article describes the collaboration between Ophirex, a Public Benefit Corporation developing the oral secretory phospholipase A2 (sPLA2) inhibitor varespladib, and the United States military, which has identified a capability gap in snakebite treatment for forward-deployed personnel. The partnership was driven by a shared requirement for a shelf-stable, easy-to-administer, snake-species-agnostic therapy suitable for use prior to definitive medical care. A central insight of the program was that military operational requirements and global public health needs converged around the same product characteristics, enabling a strategically aligned development effort. From early proof-of-concept studies through regulatory pathway definition and advanced development, the Military–Ophirex partnership integrated operational requirements, regulatory planning, and iterative risk mitigation to advance manufacturing, nonclinical, and clinical development. This work provides both practical insights into complex drug development and a case study in how structured partnerships can carry innovation through translation in underfunded and operationally challenging conditions.